The CEOi Alzheimer’s Blood Test Performance Database
As innovation with blood tests for Alzheimer’s disease accelerates, understanding how each test performs against established standards is essential to making evidence-based decisions for patient care.
The CEOi Alzheimer’s Blood Test Performance Database addresses this need. This transparent resource brings clarity to the complex landscape of Alzheimer’s blood tests by showing how the performance of available blood tests compares to published performance standards recommended by CEOi’s BBM Workgroup.
Approach
Data Submission: CEOi engaged companies with available blood tests for Alzheimer’s disease in the US, requesting they complete a standardized data table and provide a publicly available source to support the submitted information.
Quality Check: Once data submissions were received, CEOi conducted an independent quality check. Each dataset in the database is clearly labeled with its source.
Study Population: Only data from cognitively impaired individuals are included in the database. If data have been adjusted to exclude cognitively unimpaired participants, this is clearly noted in the respective data table.
Click below for more information on specific tests
For support navigating the database, click here.
-
Mayo Clinic Laboratories
p-Tau217
-
Lucent Diagnostics
LucentAD Complete (p-Tau 217, Aβ42/40, NfL, and GFAP)
-
Lucent Diagnostics
LucentAD p-Tau 217
-
CertuitAD
P-tau217
-
Quest Diagnostics
AD-Detect™ Beta-Amyloid 42/40 Ratio
-
Quest Diagnostics
AD-Detect™ Phosphorylated tau217 (p-tau217)
-
Quest Diagnostics
AD-Detect™ (Aβ 42/40 and p-tau217)
-
Quest Diagnostics
Aβ 42/40, p-tau217, and ApoE Evaluation
-
Neurocode
P-Tau217
-
C2N Diagnostics
PrecivityAD2™ (Aß42/40 Ratio and p-tau217/np-tau217 Ratio)
-
C2N Diagnostics
PrecivityAD® (Aß42/40 Ratio, ApoE and Age)
This page will be updated as new data is submitted.
Fujirebio Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio is unable to share data while under its current FDA review; Labcorp has not provided data to date.
Contact us.
If you are interested in submitting your data to the Performance Standards Database, or have questions or comments on the existing data, please complete this form.
The Global CEO Initiative on Alzheimer’s Disease
CEOi founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. It is convened by UsAgainstAlzheimer’s.